NasdaqGS:IMVTBiotechs
How Investors Are Reacting To Immunovant (IMVT) $550 Million Follow-On Equity Raise And Dilution
In December 2025, Immunovant, Inc. completed a follow-on equity offering of approximately US$550.2 million, issuing 26,200,000 common shares at US$21 each, with a small discount on part of the deal.
This sizeable capital raise, coming through both a completed and a filed follow-on offering, materially expands Immunovant’s financial resources while increasing equity dilution for existing shareholders.
We’ll now examine how this large follow-on equity raise, and the resulting balance between...